Avantor: Q2 Earnings Insights

Shares of Avantor AVTR rose 3.64% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 35.71% year over year to $0.19, which beat the estimate of $0.14.

Revenue of $1,479,000,000 declined by 3.46% year over year, which beat the estimate of $1,450,000,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Avantor hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Jul 29, 2020

Time: 05:00 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fir.avantorsciences.com%2Finvestors%2Fevents-and-presentations%2Fdefault.aspx&eventid=2399364&sessionid=1&key=BC38D321EB28CBD6C8C92019E8DB7967&regTag=&sourcepage=register

Price Action

Company's 52-week high was at $19.75

Company's 52-week low was at $6.66

Price action over last quarter: Up 17.67%

Company Overview

Avantor Inc is involved in providing products and services to biopharma, healthcare, education and government, and advanced technologies and applied materials industries. The company's offerings include materials and consumables, equipment and instrumentation and services and specialty procurement. Its brand profile consists of NuSil, RANKEM, POCH, BeneSphera, and Macron Fine Chemicals among others. The firm operates in three geographical segments namely Americas, Europe, and AMEA. It generates a majority of its revenue from the Americas.